मैट्रिक्स
 
 
सन फार्मा एडवांस्ड रिसर्च कंपनी > कंपनी इतिहास > Pharmaceuticals > कंपनी इतिहास का सन फार्मा एडवांस्ड रिसर्च कंपनी - बीएसई: 532872, NSE: SPARC

सन फार्मा एडवांस्ड रिसर्च कंपनी

बीएसई: 532872  |  NSE: SPARC  |  ISIN: INE232I01014  |  Pharmaceuticals

कंपनी इतिहास - सन फार्मा एडवांस्ड रिसर्च कंपनी
2007 - Sun Pharma Advanced Research Co.Ltd was formed in the year
 2007, with separation of India's leading specialty pharma company,
 Sun Pharmaceutical Industries Ltd, and its active projects in drug
 discovery and innovation into a new company. The parent company, Sun
 Pharma Industries Ltd continues to invest independently in generic
 research.
 
 - Sun Pharma Advanced Research Company Ltd (SPARCL) had allotted
 3,39,441 equity shares of Re 1 each to the bond-holders of Sun Pharma
 Industries Ltd (SPIL) on conversion of 5,500 foreign currency
 convertible bonds upon conversion. 
 
 - Balance Sheet along with the Profit and Loss Account for the year
 ended March 31, 2007  adopted and the Reports of Directors & Auditors
 thereon.
 
 - Mr. Dilip S Shanghvi and Mr. Sudhir V Valia, re appointed as the
 Directors of the Company.
 
 - According to the clause 10.2 of the scheme of arrangement of
 demerger, sanctioned by the High Court of Gujarat through its order
 dated March 01, 2007, issued on March 28, 2007 and as per
 supplementary Trust Deed dated may 18, 2007, the FCCB's holders of
 Sun Pharma Industries Ltd, are entitled for one equity share of Re 1
 each of the company for every equity share of Rs.5 each of SPIL.
 
 2011
 
 - Sun Pharma announces USFDA approval for DOCEFREZ (docetaxel) for
 Injection.
 
 2012
 
 -SPARC - Starhaler Device finalist at Medical Design Excellence
 Awards
 
 -Sun Pharma Advanced Research Company Ltd Issues Rights in the Ratio
 of 1:7
 
 2013
 -SPARC to provide update on NCE & NDDS programs
 
 2014
 -SPARC Announces India Approval for Paclitaxel Injection Concentrate
 for Nanodispersion (PICN)
 
 2017
 -  SPARC has received a Complete Response Letter (CRL) from the USFDA
 for its New Drug Application (NDA) for Elepsia XRTM, Levetiracetam
 extended-release tablets 1000 mg and 1500 mg.
 
 
 
 
 
 
स्रोत: रेलीगरे टेचनोवा

न्यूज़ फ़्लैश

  • MARKET CUES : FIIs ने कैश में `637 Cr की खरीदारी की
  • MARKET CUES : DIIs ने कैश में `468 Cr की बिकवाली की
  • MARKET CUES : FIIs ने F&O में `2005 Cr की खरीदारी की
  • MARKET CUES : इंडेक्स फ्यूचर्स में `494 Cr की खरीदारी
  • MARKET CUES : इंडेक्स ऑप्शंस में `2119 Cr की खरीदारी
  • MARKET CUES : स्टॉक फ्यूचर्स में `596 Cr की बिकवाली
  • MARKET CUES : स्टॉक ऑप्शंस में `12 Cr की बिकवाली
  • CITI ON DLF : Sell रेटिंग, लक्ष्य `144/Sh
  • MS ON DLF : Overweight रेटिंग, लक्ष्य `211/Sh
  • CLSA ON DLF : Buy रेटिंग बरकरार, लक्ष्य `190/Sh

अभी देखें

OUR WINNING PICKS

DID YOU INVEST?

INTRADAY PICKS!

(August 06, 2018)

AT (Rs)



GAIN (Rs)

ALL TIME WINNERS

RECO PRICE

PEAK PRICE

OUR PACKAGES

Super Combo

Powerful mix of both trader and investor packs with timely expert advice.

Technical

Designed especially for traders looking to tap the profit opportunities of volatile markets.

Fundamental

For all investors looking to unearth stocks that are poised to move.